Status:
COMPLETED
Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Cannabis Use
Eligibility:
All Genders
18-55 years
Brief Summary
Background: \- Individuals with schizophrenia or schizoaffective disorders have a high prevalence of cannabis use. Understanding some of the environmental factors that maintain cannabis use, such as ...
Detailed Description
Objective: The use of cannabis is prevalent in people with schizophrenia, and has been linked both to onset of illness and worsening of symptoms. Craving in persons with schizophrenia who use cannabis...
Eligibility Criteria
Inclusion
- INCLUSION AND EXCLUSION CRITERIA FOR SCHIZOPHRENIA PATIENTS:
- INCLUSION CRITERIA:
- 18-55 year old males and females
- Lifetime history of at least 50 cannabis uses and average cannabis use of once per month (or average use of once per month prior to hospitalization, if inpatient)
- Current DSM-IV diagnosis of schizophrenia or schizoaffective disorder
- Stable antipsychotic regimen (4 weeks on antipsychotic regimen and 30 days at current dose)
- Medically healthy as determined by screening criteria
- Agrees to wear a head mounted display (HMD) for a period of time generally not exceeding 45 minutes
- EXCLUSION CRITERIA:
- DSM-IV diagnosis of active alcohol or substance abuse (besides cannabis or nicotine) in the past 1 month or dependence within the past 6 months
- Current use of any medication that would interfere with the protocol in the opinion of MAI (dronabinol, varenicline, bupropion, etc)
- History of head injury, seizures, stroke, or severe motion sickness
- Positive urine toxicology screen for agents besides cannabis for substances other than cannabis or those used for therapeutic purposes: Participants who have an initial positive urine toxicology screen for substances other than those used for therapeutic purposes or cannabis will have the opportunity to return within two weeks for a second toxicology screen. If at that time the results are again positive, the participant will be excluded.
- Positive pregnancy test (if female)
Exclusion
Key Trial Info
Start Date :
September 26 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 26 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01212081
Start Date
September 26 2010
End Date
November 26 2012
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue
Catonsville, Maryland, United States, 21228